Trial Profile

Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD/FAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICI

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Carboplatin (Primary) ; Cemiplimab (Primary) ; CP-506 (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; Head and neck cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Convert Pharmaceuticals

01 Jul 2026 This trial has been suspended in Netherlands and Belgium.
07 Oct 2025 Planned End Date changed from 1 May 2026 to 1 May 2027.
07 Oct 2025 Planned primary completion date changed from 1 Feb 2026 to 1 Feb 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com